Welcome Letter

We are pleased to welcome you to Marseille for the seventh Annual Brain Metastases Research and Emerging Therapy Conference. Last year’s successful edition encouraged us to once again organize this conference. This year the meeting will be held under the auspices of EORTC, EANO and EANS. Also the French neuro-oncology group (ANOCCEF) and the French society of neuro-surgery are partners of this event. This initiative brings the multidisciplinary approach needed to develop Brain Metastases projects across several tumor types and disciplines such as breast cancer, lung cancer, melanoma, imaging, radiation oncology, pathology and molecular. It is expected that this cross-sectional meeting will stimulate innovative and insightful research in a collaborative environment and improve the standard of care and methodology of clinical research.

For this 7th edition, a special session will be dedicated to Immuno-oncology in CNS Metastases. Actually, cancer immunotherapy clinical trials are critical to bringing new and potentially lifesaving treatments to more patients with more types of cancer, and may represent the greatest hope especially for patients currently facing Brain Metastases. Highlighted topics will also cover adverse radiation effect in the era of targeted therapies, new pharmacological approaches and combined treatments in BM.

One of the objectives of this edition will be to describe the clinical problem, identify the critical points of therapeutic failure and summarize the current state of knowledge of the genetics and biology of Brain Metastases. The overarching goal of the meeting is to generate a set of research priorities that would stimulate integrated scientific and clinical investigation directed at understanding basic processes of brain metastasis and translating such insights to clinical care.

The organizing committee hopes that this meeting will provide an exceptional opportunity for you to share your collective expertise ranging from basic science to new treatments in order to facilitate ongoing studies and lay the foundation for future collaborative projects.

PROGRAM CHAIRS:
Manmeet Ahluwalia, Emilie Le Rhun, Philippe Métellus & Michael Weller

Faculty
Manmeet Ahluwalia, Cleveland, USA
Anna Sophie Berghoff, Vienna, Austria
Antoine Carpentier, Paris, France
Anthony Chalmers, Glasgow, United Kingdom
Amélie Darlix, Montpellier, France
Frédéric Dhermain, Villejuif, France
Robert Roth, Zurich, Switzerland
Patrick Roth, Zurich, Switzerland
Riccardo Soffietti, Turin, Italy
Manuel Soffietti, Turin, Italy
Frédéric Dhermain, Villejuif, France
Johan M. Kros, Rotterdam, The Netherlands
Émilie Le Rhun, Lille, France
Philine Métellus, Marseille, France
Christine Marozi, Vienna, Austria
Anouchka Modesto, Toulouse, France
Joan M. Kroos, Rotterdam, The Netherlands
Patrick Roth, Zurich, Switzerland
Robert Roth, Zurich, Switzerland
Riccardo Soffietti, Turin, Italy
Manuel Valliente, Madrid, Spain
Martin J. Van den Bent, Rotterdam, The Netherlands
Michael Weller, Zurich, Switzerland
Manfred Westphal, Hamburg, Germany

Organisation & Registration
Com&Co - Etienne Jarry
15, Bd Grawitz - 13016 Marseille, France
Tel.: +33 (0)4 91 09 70 53 - Fax: +33 (0)4 96 15 33 08
Email: ejarry@comnco.com

Program Chairs
M. Ahluwalia (US)
E. Le Rhun (FR)
P. Métellus (FR)
M. Weller (CH)

Scientific Committee
M. Ahluwalia (US)
E. Dhermain (FR)
E. Le Rhun (FR)
P. Métellus (FR)
M. Weller (CH)
Z. Ram (IL)
R. Soffietti (IT)
M. Westphal (DE)

www.brain-mets.com
**Friday October 6th**

08.30 Welcome coffee

08.45 Welcome address, P. Métellus (FR)

09.00 Diagnostic approaches

Chair: R. Soffietti (IT)

09.00 Molecular profiling to allocate patients to targeted clinical trials, J. M. Kros (NL)

09.20 Brain Metastases, M. Westphal (DE)

09.40 Leptomeningeal Metastases, E. Le Rhun (FR)

10.00 Immuno-oncology in CNS Metastases

Chair: TBC

10.00 Lessons from animal models, M. Valiente (SP)

10.20 Overview: immunotherapy in CNS Metastases, M. Ahluwalia (US)

10.40 Toxicity of immunotherapy in CNS Metastases, A. Carpentier (FR)

11.00 Coffee break and visit of the exhibition

11.20 Combined treatments for CNS Metastases

Chair: TBC

11.20 Combination of immunotherapy and radiotherapy, F. Dhermain (FR)

11.40 Combination of immunotherapy and other systemic pharmacotherapy, TBC

12.00 Combination of other systemic pharmacotherapy and radiotherapy, TBC

12.20 Keynote lecture

Chair: TBC

12.20 The future of radiotherapy for CNS Metastases: farewell to WBRT? A. Chalmers (UK)

11.30 Surgery

11.50 Radiation therapy

12.10 Perspectives in systemic treatments for BM

12.45 Lunch

13.00 Surgery

13.20 Radiation therapy

13.50 Perspectives in systemic treatments for BM

14.20 Combined treatments for CNS Metastases

Chair: TBC

14.20 Combination of immunotherapy and radiotherapy, F. Dhermain (FR)

14.40 Combination of immunotherapy and other systemic pharmacotherapy, TBC

15.00 Combination of other systemic pharmacotherapy and radiotherapy, TBC

15.10 Keynote lecture

Chair: TBC

15.10 Assessing response and clinical benefit in clinical trials enrolling patients with Brain and leptomeningeal Metastases, M. Weller (CH)

15.30 Case 1 (Syst chemo), A. Darlix (FR)

15.40 Case 2 (Immu), A. S. Berghoff (AUT)

15.50 Coffee break and visit of the exhibition

16.20 Interactive case reports (progression/criteria of evaluation)

Chairs: P. Métellus (FR) & M. Weller (CH)

15.20 Case 1 (Syst chemo), A. Darlix (FR)

15.30 Case 2 (Immu), A. S. Berghoff (AUT)

15.40 Case 3 (RT), A. Roth (CH)

15.50 Coffee break and visit of the exhibition

16.20 Keynote lecture

Chairs: M. Ahluwalia (US) & M. Westphal (DE)

16.20 Assessing response and clinical benefit in clinical trials enrolling patients with Brain and leptomeningeal Metastases, M. Weller (CH)

16.40 Case 1 (Syst chemo), A. Darlix (FR)

16.50 Case 2 (Immu), A. S. Berghoff (AUT)

17.00 Activities of EORTC BTG CNS Metastases Committee, E. Le Rhun (FR)

17.15 Guided poster walks

20.00 Gala dinner

**Saturday October 7th**

08.00 Welcome coffee

08.30 Selected oral presentations

Chair: A. Tallet (FR)

10.10 Coffee break and visit of the exhibition

10.30 Highlight 2016-2017

Chair: TBC

10.30 Basic research, A. Boire (US)

10.50 Neuprophysiology, P. Wesseling (NL)

11.10 Imaging, TBC

11.30 Surgery, P. Métellus (FR)

11.50 Radiation therapy, E. Moyal (FR)

12.10 Perspectives in systemic treatments for BM, M. J. Van den Bent (NL)

12.30 Awards – Best communication and poster – Conclusions

12.45 Lunch

Please note that this program may be further refined.

To see the latest version and to register please visit: [www.brain-mets.com](http://www.brain-mets.com)